Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMND Clearmind Medicine, Inc.

Trading 04-23 10:32:16 EDT

0.9900

-0.0100

-1.00%

High1.01	Low0.9700	Vol37.62K
Open1.01	D1 Closing1.00	Amplitude4.00%
Mkt Cap5.08M	Tradable Cap4.62M	Total Shares5.13M
T/O36.68K	T/O Rate0.81%	Tradable Shares4.66M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CMND","market":"US","secType":"STK","nameCN":"Clearmind Medicine, Inc.","latestPrice":0.99,"timestamp":1745418609503,"preClose":1,"halted":0,"volume":37619,"delay":0,"floatShares":4663409,"shares":5134786,"eps":-1.290303,"marketStatus":"Trading","change":-0.01,"latestTime":"04-23 10:32:16 EDT","open":1.01,"high":1.01,"low":0.97,"amount":36683.960945499995,"amplitude":0.04,"askPrice":1.02,"askSize":42,"bidPrice":0.96,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.290303,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"listingDate":1668142800000,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":0.97,"preClose":1,"latestTime":"09:23 EDT","volume":11619,"amount":11367.63408924,"timestamp":1745414618310},"postHourTrading":{"tag":"盘后","latestPrice":0.9801,"preClose":1,"latestTime":"19:11 EDT","volume":2167,"amount":2137.0708,"timestamp":1745363471695},"volumeRatio":0.107264},"requestUrl":"/m/hq/s/CMND/wiki","defaultTab":"wiki","newsList":[{"id":"2529500545","title":"BRIEF-Clearmind Medicine Completes The Initiation Of Its Alcohol Use Disorder Phase I/IIA Clinical Trial At All Current Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2529500545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529500545?lang=en_us&edition=full_marsco","pubTime":"2025-04-23 20:37","pubTimestamp":1745411835,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Completes The Initiation Of Its Alcohol Use Disorder Phase I/IIA Clinical Trial At All Current Clinical SitesApril 23 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDIC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA17MKZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2529071395","title":"Clearmind Medicine Completes the Initiation of Its Alcohol Use Disorder Phase I/Iia Clinical Trial at All Current Clinical Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2529071395","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529071395?lang=en_us&edition=full_marsco","pubTime":"2025-04-23 20:25","pubTimestamp":1745411100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA17MKZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2529801200","title":"Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts","url":"https://stock-news.laohu8.com/highlight/detail?id=2529801200","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529801200?lang=en_us&edition=full_marsco","pubTime":"2025-04-21 21:15","pubTimestamp":1745241300,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 21, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled \"Gazing Through the Crystal Ball.\" The event is scheduled for May 21, 2025, at 12:00 PM ET  and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates.Rick Doblin, PhD – Founder and President of the Multidisciplinary Association for Psychedelic Studies . A trailblazer in psychedelic-assisted therapy, Dr. Doblin has dedicated his career to establishing safe, legal, and ethical uses of psychedelics through rigorous scientific research.Robin Carhart-Harris, PhD – Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco . Dr. Carhart-Har","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-host-live-webinar-131500592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4181","BK4023","BK4585","CMND","HST","BK4588","MAPS","BK4007"],"gpt_icon":0},{"id":"2528371412","title":"BRIEF-Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior","url":"https://stock-news.laohu8.com/highlight/detail?id=2528371412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528371412?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:44","pubTimestamp":1744893896,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge BehaviorApril 17 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE RECEIVES NOTICE OF ALLOWANCE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2528713474","title":"Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior","url":"https://stock-news.laohu8.com/highlight/detail?id=2528713474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528713474?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 19:38","pubTimestamp":1744889886,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2528716108","title":"Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior","url":"https://stock-news.laohu8.com/highlight/detail?id=2528716108","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528716108?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 19:38","pubTimestamp":1744889880,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 17, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to its MEAI treatment for binge behavior.This new US patent provides additional intellectual property protection for the Company’s novel MEAI- based treatment in this indication and further strengthens Clearmind’s intellectual property portfolio.Dr. Adi Zuloff-Shani, CEO of Clearmind, commented: “This Notice of Allowance further strengthens our unique position in the space and growing intellectual property portfolio and reinforces the potential of our robust MEAI program. Securing foundational patent protection is a vital step in supporting our future success and in driving the development of next-generation psychedelic-derived therapeutics with the potential","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-receives-notice-allowance-113800073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND","BK4211","UBCP"],"gpt_icon":0},{"id":"2527321161","title":"Clearmind Medicine Launches First U.S. Clinical Site for Its FDA-Approved Clinical Trial to Combat Alcoholism","url":"https://stock-news.laohu8.com/highlight/detail?id=2527321161","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527321161?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:40","pubTimestamp":1744807200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nTUA31MMR5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2527028247","title":"Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism","url":"https://stock-news.laohu8.com/highlight/detail?id=2527028247","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527028247?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:40","pubTimestamp":1744807200,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 16, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind’s innovative treatment, CMND-100, in Alcohol Use Disorder  patients. This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company’s mission to provide innovative solutions for addictions, weight loss and mental health disorders such as depression and anxiety.Alcohol Use Disorder remains a major global health challenge, affecting millions of individuals worldwide. The disorder is linked to severe health complications, inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-launches-first-u-124000936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2526597372","title":"Clearmind Medicine Starts Phase 1/2a Trial of CMND-100 in Patients With Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2526597372","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526597372?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 23:27","pubTimestamp":1744298820,"startTime":"0","endTime":"0","summary":"Clearmind Medicine  said Thursday that it has started a phase 1/2a clinical trial of CMND-100 in patients will alcohol use disorder at the Johns Hopkins University School of Medicine, the company's first clinical site in the US.The biotechnology company said the trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100 and will also include preliminary efficacy evaluations to assess its potential in reducing alcohol cravings and consumption.Price: 0.95, Change: -0.03, Percent Change: -3.06","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2526569354","title":"Clearmind Medicine announces U.S. clinical site initiation for CMND-100 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526569354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526569354?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:31","pubTimestamp":1744288310,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-u-s-clinical-site-initiation-for-cmnd-100-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-announces-u-s-clinical-site-initiation-for-cmnd-100-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2526794565","title":"Clearmind Medicine Announces First U.S. Clinical Site Initiation for Cmnd-100 Clinical Trial in Patients With Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2526794565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526794565?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:25","pubTimestamp":1744287900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA7KQSDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2526558569","title":"Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2526558569","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526558569?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:25","pubTimestamp":1744287900,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, April 10, 2025  -- Clearmind Medicine Inc. ,  , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind’s innovative treatment, CMND-100, in Alcohol Use Disorder  patients. This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company’s mission to provide innovative solutions for addictions, weight loss and mental health disorders such as depression and anxiety.Alcohol Use Disorder remains a major global health challenge, affecting millions of individuals worldwide. The disorder is linked to severe health complications, i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-medicine-announces-first-u-122500938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2524118106","title":"Clearmind Launches Its Edc System to Support Its Phase I/Ii Clinical Trial of Its Meai-Based Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2524118106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524118106?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:15","pubTimestamp":1743509700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA8HBYJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGNPF","MNMD","GHRS","CMND","PSYGF","MYCOF","SEEL","MIRA","CYBN","BK4547","RLMD","ALID","FLHLF","NUMIF","QNTM","CMPS","OPTHF","SILO","KTTA","IXHL","BK4202","SPRC","SNPX","ATAI","MDXXF","BK4168","PHRRF","PBM","BK4539","ENTBF","BK4139","NRXP","BETRF","DRUG","BK4007","RVVTF"],"gpt_icon":0},{"id":"2521280806","title":"Clearmind Medicine Moves Closer to CMND-100 Trial After Alcohol Use Disorder Drug Candidate Arrives in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2521280806","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521280806?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 22:13","pubTimestamp":1742566405,"startTime":"0","endTime":"0","summary":"Clearmind Medicine  said Friday its alcohol use disorder oral drug candidate CMND-100 has reached the U.S., moving the drug closer to a planned phase 1/2a trial.The trial will evaluate the drug's safety and efficacy in lowering alcohol consumption.The study will be carried out at the Yale School of Medicine's Department of Psychiatry and Johns Hopkins University School of Medicine.The Israeli trial will be conducted at IMCA  in Israel.Price: 1.18, Change: +0.01, Percent Change: +0.43","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2521530284","title":"Clearmind Medicine’s FDA-Approved Clinical Trial for Cmnd-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2521530284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521530284?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:28","pubTimestamp":1742563680,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nTUA4GJWL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007"],"gpt_icon":0},{"id":"2521284645","title":"Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2521284645","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521284645?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 21:28","pubTimestamp":1742563680,"startTime":"0","endTime":"0","summary":"Vancouver, Canada, March  21, 2025  (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the \"Company\"), a clinical-stage biotech company focused on discovery and d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/21/3047090/0/en/Clearmind-Medicine-s-FDA-Approved-Clinical-Trial-for-CMND-100-Moves-Forward-as-Drug-Arrives-in-the-U-S-Advancing-Toward-Key-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","FORD","BK4007","BK4202"],"gpt_icon":0},{"id":"2520907613","title":"Clearmind Medicine Inc - Signs Loi With Polyrizon for Intranasal Formulation for Its Psychedelic-Based Treatment Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2520907613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520907613?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:36","pubTimestamp":1742384198,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","PLRZ","BK4007"],"gpt_icon":0},{"id":"2520907205","title":"Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2520907205","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520907205?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:35","pubTimestamp":1742384100,"startTime":"0","endTime":"0","summary":"Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments. Under the terms of the non-binding LOI, Clearmind and Polyrizon will conduct research and development efforts to achieve a proof of concept for an intranasal formulation of MEAI and MEAI-PEA combinations. The companies will assess the feasibility of intranasal drug delivery, which offers several potential advantages over traditional administration methods, including faster absorption and onset of action, high bioavailability for increased therapeutic effects and enhanced patient compliance due to non-invasive administration.“This collaboration represents an exciting step forward in our efforts to continue innovating psychedelic-based treatments,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “We believe intranasal administration has the potential to improve patient outcomes by providing a faster-acting, more efficient, and user-friendly treatment option. This agree","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-evaluate-intranasal-delivery-psychedelic-113500685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND","PLRZ"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QNTM","PSYGF","ENTBF","SPRC","SEEL","BK4168","RLMD","SILO","KTTA","BK4539","IXHL","BETRF","GHRS","CYBN","BK4547","NRXP","MNMD","CMPS","DRUG","CMND","AGNPF","ENVB","ALID","FLHLF","BK4202","MDXXF","RVVTF","SNPX","MIRA","ATAI","NUMIF","PBM","OPTHF","MYCOF","BK4139","BK4007","PHRRF"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.clearmindmedicine.com","stockEarnings":[{"period":"1week","weight":0.087},{"period":"1month","weight":-0.1071},{"period":"3month","weight":-0.3103},{"period":"6month","weight":-0.3506},{"period":"1year","weight":-0.1597},{"period":"ytd","weight":-0.2754}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.","exchange":"NASDAQ","name":"Clearmind Medicine, Inc.","nameEN":"Clearmind Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Clearmind Medicine, Inc.,CMND,Clearmind Medicine, Inc.股票,Clearmind Medicine, Inc.股票老虎,Clearmind Medicine, Inc.股票老虎国际,Clearmind Medicine, Inc.行情,Clearmind Medicine, Inc.股票行情,Clearmind Medicine, Inc.股价,Clearmind Medicine, Inc.股市,Clearmind Medicine, Inc.股票价格,Clearmind Medicine, Inc.股票交易,Clearmind Medicine, Inc.股票购买,Clearmind Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Clearmind Medicine, Inc.(CMND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Clearmind Medicine, Inc.(CMND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction